Dan Lichtman, President and CEO of NoAb BioDiscoveries, said “This partnership with SAGE Labs strengthens our service offering in drug discovery research. Preclinical researchers will benefit from the combined expertise and leadership of NoAb and SAGE.” NoAb BioDiscoveries is a preclinical Contract Research Organization that offers a wide range ADME-PK Discovery services, specializing in in vivo models, in vitro assays and bioanalytical support.
In addition to standard drug disposition studies, specific surgical catheterization points available at NoAb BioDiscoveries include Jugular Vein, Carotid Artery, Hepatoportal Vein, Bile Duct, and Intestinal Subsections. Such customized models form an important component of the tools that an investigator can use to address unique and specific questions about their compounds.
For further information, please contact Sal Lemus, Business Development Manager, NoAb BioDiscoveries at 905 814-5238 ext. 235 or slemus@noabbiodiscoveries.com.
Web site: www.noabbiodiscoveries.com